Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium, 3000
- UZ Leuven
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Montréal, Quebec, Canada, H3A 2B4
- Montreal Neurological Institute Clinical Research Unit
-
-
-
-
Hérault
-
Montpellier, Hérault, France, 34295
- Hopital Gui de Chauliac, Service de Neurologie
-
-
Paris
-
Paris cedex 13, Paris, France, 75013
- Groupe Hospitalier Pitie-Salpetriere
-
-
-
-
-
Berlin, Germany, 13125
- Charité - Campus Virchow-Klinikum
-
Hannover, Germany, 30625
- Medizinische Hochschule Hannover
-
Jena, Germany, 07743
- Universitaetsklinikum Jena
-
Ulm, Germany, 89081
- Universitaetsklinikum Ulm
-
-
-
-
-
Dublin, Ireland, Dublin 9
- Beaumont Hospital
-
-
-
-
CX
-
Utrecht, CX, Netherlands, 3584
- UMC Utrecht
-
-
-
-
-
St. Gallen, Switzerland, 9007
- Kantonsspital St. Gallen
-
-
-
-
West Midlands
-
Sheffield, West Midlands, United Kingdom, S102JF
- Royal Hallamshire Hospital
-
-
-
-
California
-
San Diego, California, United States, 92103
- University of California San Diego Medical Center
-
San Francisco, California, United States, 94115
- California Pacific Medical Center
-
-
Florida
-
Tampa, Florida, United States, 33612
- University of South Florida
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- The Emory Clinic
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Hospital
-
-
Massachusetts
-
Charlestown, Massachusetts, United States, 2129
- Massachusetts General Hospital, MA
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, EC037
- Penn State Milton S. Hershey Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Key Inclusion Criteria:
- A diagnosis of sporadic or familial ALS
- ALS onset within ≤5 years
- Must be 16 to 85 years of age, inclusive, for sites in the United States and 18 to 85 years of age, inclusive, for all sites outside of the United States
Key Exclusion Criteria:
- History of or positive test result at Screening for human immunodeficiency virus (HIV)
- History of or positive test result at Screening for hepatitis C virus (HCV) antibody or hepatitis B virus (HBV)
- Possibility of neuromuscular weakness other than ALS
- Unspecified reasons that, in the opinion of the site Investigator, make the subject unsuitable for enrollment or unlikely to be able to complete, at a minimum, the Month 6 Visit
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)
Time Frame: Baseline to Month 6 and Baseline to Month 12
|
EIM is an electrophysiological technique in which current is applied to a muscle of interest and resultant voltage and impedance are measured.
These measured parameters reflect the conductivity of underlying tissue and presumably the pathologic state of denervated muscle in an ALS participant
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)
Time Frame: Baseline to Month 6 and Baseline to Month 12
|
CMAP is a standard electrophysiological measure generated by maximally stimulating a nerve such that all muscle fibers innervated by the respective nerve are depolarized.
Reduction of CMAP amplitude reflects loss of motor axons and, therefore, is directly relevant to ALS.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)
Time Frame: Baseline to Month 6 and Baseline to Month 12
|
Optional, to be administered at each site's Investigator's discretion.
MUNE is used to estimate the number of functioning motor units.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)
Time Frame: Baseline to Month 6 and Baseline to Month 12
|
MUNIX estimates functioning motor units within a muscle.
CMAP and surface electromyography potentials (surface interference patterns) are obtained at various levels of voluntary effort, and MUNIX is estimated using power and area of CMAP and surface interference patterns.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)
Time Frame: Baseline to Month 6 and Baseline to Month 12
|
HHD tests isometric strength of multiple muscles using standard participant positioning.
Approximately 10 muscle groups will be examined (per each side) in both upper and lower extremities.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)
Time Frame: Baseline to Month 6 and Baseline to Month 12
|
Vital capacity will be measured by means of an SVC test, administered in the upright position.
Upright SVC will be determined by performing 3 to 5 measures, in accordance with criteria established by the American Thoracic Society and the European Respiratory Society.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)
Time Frame: Baseline to Month 6 and Baseline to Month 12
|
The ALSFRS-R has been demonstrated to predict survival.
The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills.
There are a total of 12 questions, each scored from 0 to 4 for a total possible score of 48 [Cedarbaum 1999], with higher scores representing better function.
|
Baseline to Month 6 and Baseline to Month 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM
Time Frame: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for CMAP
Time Frame: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for MUNE
Time Frame: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for MUNIX
Time Frame: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for HHD
Time Frame: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for SVC
Time Frame: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R
Time Frame: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival
Time Frame: Baseline to Month 24
|
Baseline to Month 24
|
|
Comparison between 6-month changes for muscle electrophysiological measures
Time Frame: Baseline to Month 12
|
Baseline to Month 12
|
|
Comparison between 6-month changes for muscle strength measures
Time Frame: Baseline to Month 12
|
Baseline to Month 12
|
|
Comparison between 6-month changes for functional measures
Time Frame: Baseline to Month 12
|
Baseline to Month 12
|
|
Comparison of molecular biomarkers with disease progression
Time Frame: Baseline to Month 12
|
Baseline to Month 12
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 999AS003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.